
By
Boyd E. Haley Ph.D.,
Professor and Chair,
Department of Chemistry,
University of Kentucky,
Lexington, KY 40506-0055
e-mail, behaley@uky.edu
This is
the html version of the following pdf file
http://www.fda.gov/ohrms/dockets/dailys/02/Sep02/091602/80027dd5.pdf
Abstract: Mercury(II) or Hg2+, is
neurotoxic and when exposed to normal brain tissue
homogenates, is capable of causing many of the same
biochemical aberrancies found in Alzheimer’s diseased
(AD) brain. Also, rats exposed to mercury vapor show some
of these same aberrancies in their brain tissue.
Specifically, the rapid inactivation of the brain thiol-sensitive
enzymes tubulin, creatine kinase and glutamine synthetase
occurs on the addition of low micromolar levels of Hg2+
or exposure to mercury vapor, and these same enzymes are
significantly inhibited in AD brain. Further, extended Hg2+
exposure to neurons in culture has been shown to produce
three of the widely accepted pathological diagnostic
hallmarks of AD. These are elevated amyloid protein,
hyper-phosphorylation of Tau, and formation of
neurofibillary tangles. The hypothesis is that mercury and
other blood-brain permeable toxicants that have enhanced
specificity for thiol-sensitive enzymes are the
etiological source of AD. Included in this category are
other heavy metals such as lead and cadmium that act
synergistically to enhance to toxicity of mercury and
organic-mercury compounds, like thimerosal that is found
in vaccines and other medicines. This hypothesis is also
able to explain the genetic susceptibility to AD that is
expressed through the APO-E gene family. Specifically, a
reduction of APO-E gene types carrying cysteines decreases
the ability to remove mercury and other thiol-reactive
toxicants from the cerebrospinal fluid. This increases
brain exposure to thiol-reactive toxicants and the risk of
AD.
RATIONALE FOR THE HYPOTHESIS:
AD is a disease of unknown etiology. However, it is
widely accepted that most AD is not directly genetically
inherited and that some external vector, such as a
toxicant exposure or an infection, must be involved for
the disease to progress into a clinically observable
condition. In the USA the rate of AD is very similar for
rural versus urban peoples and it does not vary
appreciably from state to state. Therefore, if a toxicant
is involved then this toxicant must be of a very personal
nature, like what we eat or what is placed into our bodies
through other sources such as dental fillings, vaccines,
etc.
The involvement of infectious agents such as bacteria,
virus or yeasts; while possible at this time, seems not to
be directly involved. This is based on the huge amount of
National Institutes of Health (USA) and other world-wide
funds spent on AD to identify the causal factors and they
have not detected a consistent microbial vector. If an
infectious agent were involved (like in AIDS and polio) it
seems as if it would have been identified by now. However,
focal infections caused by microbes in the oral cavity
must still be considered as these microbes are known to
produce toxicants such as hydrogen sulfide, methyl-mercaptan,
gliatoxin and other compounds that inhibit thiol-sensitive
enzymes.
For any toxicant, or class of toxicants, to be proposed
as involved in the etiology of AD they must be available
equally to individuals living in markedly different
locations. The toxicant proposed must explain the genetic
susceptibility concept of AD. Further, under experimental
conditions the toxicants must be able to cause the
exacerbation of the many biochemical aberrancies found in
AD brain. Based on our research and a literature review,
mercury and mercury containing compounds from dental
amalgams, vaccines, other medicinals and preservatives
used in paints, seed grains, etc. represent a class of
compounds that fill this requirement.
Mercury and organic mercurials are neurotoxicants.
Further, the enzyme inhibitory effects of mercury are
synergistically enhanced by exposures to other toxicants
such as lead and cadmium (smokers). Even the simultaneous
presence of EDTA (ethylene-diamine-tetraacetic acid, a
common food additive) or metal binding antibiotics such as
tetracycline can enhance mercury toxicity. Therefore, any
determination of a safe level of mercury exposure using
rats in a cage being feed carefully monitored food and
water is not reliable for determination of a "safe
level of exposure to mercury" for humans. The fact is
that science does not know what the combined toxic effects
of many toxicants or enhancers of toxicity would be if
present with mercury and therefore cannot identify a safe
level of exposure.
Therefore, thiol-reactive toxicants such as mercury,
cadmium, lead and certain organics are rational
suggestions as being exacerbating factors for AD, or
possibly even causal. However, mercury is the one toxicant
that has been shown to reproduce many of the biochemical
aberrancies and diagnostic hallmarks of AD. Also, mercury
exposure is readily available to most humans. It is
reasonable to propose that exposure to mercury is one of
the major toxic factors involved in early onset AD.
Further, that simultaneous exposures to other toxicants or
factors enhance the toxicity of mercury and hasten the
onset of AD, especially in those individuals who are
genetically susceptible.
RESEARCH REVIEW AND RESULTS:
Enzyme Inhibition and Protein Partitioning Results.
Research regarding Alzheimer’s disease (AD) done in
our laboratory in the late 1980s was directed towards
detecting aberrancies in the nucleotide binding proteins
of AD post-mortem brain tissue versus age-matched,
non-demented control brain samples. Basic to all of our
findings was the following observation. Two very important
brain nucleotide binding proteins, tubulin and creatine
kinase (CK), showed greatly diminished activity and
nucleotide binding ability. Further, they were abnormally
partitioned into the particulate fraction versus the
soluble fraction of AD brain tissue by simple
centrifugation (1,2).
Both tubulin and CK are proteins that bind the
nucleotides GTP (guanosine-5’-triphosphate) and ATP
(adenosine-5’-triphosphate), respectively. We use a
"photoaffinity labeling" technology to determine
the availability of these binding sites before and after
addition of mercury or other toxicants (21). This
technology is explained in detail at www.altcorp.com for
those interested in the detailed chemistry. Using this
technology our laboratory has demonstrated that both
tubulin and CK had diminished biological activity in AD
brain compared to age-matched controls. Since AD is not
directly a genetically inherited disease we searched for
possible toxicants that might mimic the specific findings
observed in AD brain.
Our first finding was simple and straight-forward.
After testing numerous heavy metals we observed that only
Hg2+ could mimic the AD effect in homogenates
of normal brain at concentrations that might be expected
to be found in brain (3,4). The observation was that Hg2+
at very low micromolar levels (@
1 micromolar) could rapidly and selectively abolish the
GTP binding activity of tubulin (Mr = 55,000
daltons) without any noticeable effect on the other GTP
binding proteins protein(s) observed at an Mr
of about 42,000 daltons, that are present in both control
and AD brain at approximately equal levels. Therefore,
concerning heavy metals the addition of only mercury at
low micromolar levels to control brain homogenates gave a
GTP binding profile that was identical to that observed in
AD brain and that chelation of Hg2+ by EDTA did
not prevent but enhanced this effect (4,5,6). Further,
additional results have shown that the addition of Hg2+
to control brain homogenates not only caused the decrease
in nucleotide interaction but could also support the
abnormal partitioning of tubulin into the particulate
fraction as observed in AD brain (7). This was especially
effective in the presence of other divalent metals, such
as zinc, which is elevated in AD brain. The recent video
demonstrating Hg2+ specific stripping the
tubulin from the neurofibrils shows the tubulin abnormally
aggregating at the base of the neuron, supporting the
partitioning we observed in brain homogenates (http://movies.commons.ucalgary.ca/mercury).
It is critical to understand that both tubulin and CK
in normal brain are found primarily in the soluble
fraction of a homogenate. Yet, both proteins appear of
normal size and unmodified on reducing polyacrylamide gel
electrophoretic analysis (PAGE). This indicates that both
intact tubulin and CK have formed crosslinks with other
proteins that are insoluble under physiological
conditions. Yet, these crosslinks are readily disrupted by
the common dithiolthreitol (DTT) reduction procedure used
before PAGE. What tubulin and CK have in common is that
both have a very reactive sulfhydryl in their nucleotide
binding sites that, if modified, inhibits their biological
activity (14, 15).
Mercury has a very high affinity for sulfhydryls and
has been proven to be a potent inhibitor of the biological
activity of both of these proteins. Also, mercury is
divalent and can form crosslinks between soluble proteins
like tubulin and CK and is known to cause protein
aggregation. A generalized single step reaction would be
as given in reaction 1.
1: Protein-A-SH + Protein-B-SH + Hg2+ Þ
Protein-A-S-Hg-S-Protein-B + 2 H+
This chemistry would allow the formation of aggregates
that would abnormally appear in the particulate fraction.
Due to its dithiol structure DTT is an excellent chelator
of mercury. The massive amounts of DTT used in reducing
gels could chelate and remove mercury from the proteins
resulting in their becoming soluble again and migrating as
unmodified on gel electrophoresis as observed as shown in
reaction 2.
2. Protein-A-S-Hg-S-Protein-B + DTT Þ
Protein-A-SH + Protein-B-SH + DTT-Hg
The correct criticism of any homogenate test is that it
may not occur in a living animal. Therefore, experiments
were done to determine if mercury vapor, the primary form
that escapes from dental amalgams, could mimic the effect
in rats exposed to such vapor for various periods of time
(5). Rats are different from humans in that they can
synthesize vitamin C whereas humans have to ingest vitamin
C. Vitamin C is thought to be somewhat protective against
heavy metal toxicity and other oxidative stresses.
However, we observed that the tubulin in the brains of
rats exposed to mercury vapor lost between 41 and 75
percent of the nucleotide binding capability demonstrating
a similarity to the aberrancy observed in AD brain and
confirming the homogenate results (5).
There is also an "excito-toxic" amino acid
hypothesis for the cause of AD wherein excito-toxic amino
acid glutmate builds up in brain tissue causing neuronal
death. This is a reasonable hypothesis and could co-exist
with the thiol-sensitive enzyme/mercury hypothesis. The
activity of Hg2+ sensitive glutamine synthetase
(GS) was measured in AD brain and the amount of GS in the
cerebrospinal fluid of AD versus control patients was
determined. GS was found it to be inhibited in AD brain
and copies of GS were elevated in the cerebrospinal fluid
(12, 22). It has also been predicted by two groups that
the elevation of GS in the cerebrospinal fluid of AD
patients has potential as a diagnostic aid for AD (12,16).
However, it is reasonable to conclude that brain GS would
be rapidly inhibited by Hg2+ produced by
oxidation of mercury vapor. This inhibition would cause a
rise in glutamate based excito-toxicity and could cause
neuron death. Further, glutamate is transported by
molecular motors down the microtubules that are destroyed
by Hg2+. Therefore, both the metabolism and
transport of glutamate would be immediately affected by
exposure to mercury. The measurement of GS in
cerebrospinal fluid is most likely a measure of glial cell
toxicity and death as would be expected in several central
nervous system diseases, including AD.
Illnesses that lower our metabolic energy levels also
lower our ability to synthesize the reducing equivalents
that allow our body to bind and dispose of excess mercury.
Hg2+ is known to inhibit the metabolic
processes in mitochondria that produce ATP and NADH by
inhibiting the enzymes of the citric acid cycle and the
electron transport system. These nucleotides are
absolutely required for both the synthesis of reduced
glutathione (GSH) and to reduce glutathione after it is
oxidized. GSH in the reduced state is the major
biomolecule involved in the natural removal of mercury
from the body. Therefore, as mercury slowly accumulates in
the body it weakens the body’s natural defense against
all forms of other heavy metal toxicities and increases
the overall oxidative stress expressed by reactive oxygen
species formation. It is well known that AD brain tissue
suffers from greater oxidative stress in all cellular
components versus similar tissues from control subjects.
This would be expected and it is well documented that
mercury increases oxidative stress in biological tissues.
Further, Hg2+ is well known to inhibit numerous
other enzymes important to neurological function,
including the Na/K ATPase that is necessary for recovery
from a nerve-action potential. Therefore, the many
numerous aberrancies observed in AD brain would be
expected within a hypothesis that proposes exposure to Hg2+
is a major contributor to this disease.
Relevant Mercury Exposures and Measurments.
Mercury from Dental Amalgams;
The fact that mercury has inhibitory effects on tubulin,
CK and GS and that these proteins are proven to be
aberrantly inhibited in AD does not alone conclusively
prove that mercury exposure causes AD. However, it
definitely proves that chronic, daily exposure to mercury
would at least exacerbate the clinical conditions of AD.
Is such an exposure to mercury likely? The answer is yes,
and this makes mercury involvement in AD plausible.
First, the question must be addressed if there is
enough mercury in an amalgam filling to continue a low
chronic level exposure for years? The answer is yes. For
example, if a single large amalgam filling contained 1
gram of mercury (1 million micrograms) and lost a
significantly toxic 10 micrograms per day there would be
enough mercury for 100,000 days or about 274 years of
exposure. A small tenth of a gram mercury filling would
last 27 years. So enough mercury is within amalgam
fillings to provide a consistent chronic toxic exposure
for the life of most fillings.
Second, does mercury emit from amalgams at a rate that
should cause concern? The answer is yes. Dental amalgams,
or "silver fillings" as organized dentistry
calls them, are approximately 50% mercury by weight and it
is quite easy to demonstrate that mercury vapors readily
emit from these fillings. The actual amount can only be
determined with the amalgam in a closed container and the
amount of mercury released being determined using solid,
time proven chemical techniques and instrumentation. The
accurate level of mercury released cannot be accomplished
on amalgams in the mouth. In a carefully designed study in
a sealed container Chew et al. tested the "long term
dissolution of mercury from a non-mercury-releasing
amalgam (trade name Composil)" (9). Their results
demonstrated "that the overall mean release of
mercury was 43.5 +/-3.2 micrograms/cm2/24hr,
and the amount of mercury released remained fairly
constant during the duration of the experiment (2
years)".
In my opinion, this 43.5 micrograms/cm2/day
is not an insignificant amount of mercury exposure if one
considers the number of years a 70 year old individual
living today may have been exposed to chronic mercury
levels from his amalgams. Additionally, 43.5 micrograms/cm2/day
is the level released without galvanism, excess heat, or
pressure from chewing, all factors that increase mercury
release from amalgams in the mouth (26).
Some may disagree with the figure presented above and
indeed, amalgams of different manufacture may release more
or less. However, the pro-amalgam supporters have not
published any carefully controlled study similar to the
one above repudiating the finds of this research group.
They definitely have all of the scientific laboratory
expertise needed to do this. Instead, they utilize
"estimates" of release based on urine and blood
levels that are widely known to vary dramatically with
time and not to be reliable. In judging science one looks
for what is not published that obviously should have been.
Does the Presence of Amalgams Contribute
Significantly to Mercury Body Burden?
There have been numerous published reports of increased
tissue mercury levels in subjects and the relationship to
increased number of amalgams fillings (see 10, 11, 25 and
references therein). Also, the World Health Organization
Scientific Panel found ranges of mercury exposures from 3
to 70 micrograms/day with the bulk being from amalgam
fillings (31). Data relevant to this question was
addressed by a recent NIH study using 1,127 military
personnel (20). Soldiers in this study had an average of
20 amalgam surfaces with ranges from 0 to 66 surfaces.
Each 10 surfaces increased the urine mercury level
1microgram/liter or an average of 4.5 micrograms/day. This
study indicated that individuals with an average number of
amalgam fillings had about 4.5 times the urine mercury
levels as controls without amalgams. Those soldiers with
over 49 surfaces averaged over 8 times the urine level
observed in the non-amalgam controls. Further, the blood
and urine mercury levels corresponded well with the number
of amalgam fillings (20). The results above are consistent
with an earlier study where urinary mercury levels dropped
by a factor of 5 after the removal of several amalgam
fillings. The conclusion of the authors was that mercury
from dental amalgams exceeds that from all forms of food,
air and fluids (23). All of the data on urine or blood
mercury levels must be considered with the knowledge that
approximately 80% of inhaled mercury vapor is retained in
the body. Mercury typifies a "retention"
toxicity and much of the mercury taken into the body is
absorbed by the solid tissues. The amount in urine
represents mercury being excreted. However, the main
question is how much is being retained in the different
body tissues.
In contrast to other reports there was published in the
J. American Dental Association research that measured
mercury levels in brain and other neurological tissues and
concluded "Our results do not support the hypothesis
that dental amalgam is a major contributor to brain Hg
levels. They also do not support the hypothesis that Hg is
a pathogenetic factor in AD (25)." I can’t explain
how amalgams can increase blood mercury levels and not
increase brain mercury levels. However, these researchers
presented data showing no significant increase in Hg level
in several brain regions between control and AD subjects.
They surprisingly included data showing that the Hg levels
in control olfactory region was more than double that of
the corresponding AD olfactory tissue. This olfactory
mercury increase in control subjects could have several
explanations.
One explanation could be they were not precise in
estimating the amount of mercury exposures of their
subjects and the controls they selected were much more
exposed to mercury than the AD subjects selected. The
olfactory region is outside the blood-brain barrier and
should be a consistent internal standard for mercury
exposure in the air breathed in by the subjects.
Another explanation would be that the controls, even
though exposed to more than double the mercury levels of
the AD subjects, as evidenced by the olfactory region Hg
levels, had a mechanism that protected their brain tissues
from also having double the mercury levels. If this were
true, then dividing the brain mercury levels by the
olfactory mercury levels would give results that clearly
show a significant ability of the controls to have a
mechanism that protects brain tissue from mercury that is
lacking in the AD subjects. This mechanism could be the
presence of the protective APO-E protein genotypes (see
below) and other predisposition factors not yet known.
The debate continues on whether or not human mercury
exposures reach levels in the brain and other tissues that
could be considered toxic or harmful (24,25). There are
several reasons why the brain levels of mercury would not
directly correlate to the damage being done. The level of
selenium in the diet, which could bind with mercury
rendering it less toxic, is the most straight-forward
example. Also, the determination of the levels of mercury
toxicity that could cause neurological disease has been
done using animals, such as rats and monkeys, under
tightly controlled laboratory conditions where the diet is
carefully monitored to exclude other toxicants. Further,
any test animal that becomes ill or infected by microbial
sources is removed from the study. However, humans do not
live under such restricted conditions. For example, we are
exposed to numerous infections and additional heavy metal
imbalances in AD brains have been reported numerous times.
Cigarette smokers are exposed to excess cadmium (Cd2+)
and lead (Pb2+) toxicity is not that uncommon
in the inter-city environment or for those exposed to
leaded gasoline fumes for many years. This means that the
synergistic toxicities of combined heavy metals must be
considered for humans.
It is also questionable whether or not brain mercury
levels should be expected to remain high in AD brain. A
report by Hock et al. (27) stated that in early onset AD
the blood levels of mercury were almost three fold higher
than the control groups and that these increases were
unrelated to the patients’ dental status. The concluded
that the explanation of increased mercury in AD would
include yet unidentified environmental sources or release
from the brain tissue with the advance in neuronal death.
The AD brain loses 25% of its average weight by time of
death making the latter explanation reasonable. It is a
well-known biochemical event that cells or tissues rid
themselves of denatured, unusable protein.
The inhibition and break down of neuronal tissue may
also explain another observation related to AD. It is
documented that AD patients have elevated olfactory
thresholds and impaired odor identification. It is further
suggested that in patients with mild cognitive impairment,
olfactory problems may have clinical value as an early
diagnostic predictor for diagnosis of AD(28, 29, 30).
Mercury in the oral cavity must interact with the
olfactory bulb. Due to the neurotoxicity of mercury, this
could impair olfactory sensitivity. Also, based on our
hypothesis impaired olfactory response would almost have
to occur.
Our laboratory has shown that one can add various
metals to human brain homogenates to levels that alone do
not affect nucleotide binding to tubulin, yet the very
presence of these metals synergistically increases the
toxicity of Hg2+. That is, the presence of Pb2+,
Zn2+ and Cd2+, at non-toxic levels,
decrease the amount of Hg2+ required for 50%
inhibition of tubulin or creatine kinase viability. It is
important to remember the "Periodic Chart of the
Elements" which places Zn, Cd and Hg in the same IIB
category and all have high affinity for thiol groups. In
other words, mercury is much more toxic in the presence of
other metals that compete with mercury for the binding
sites on protective biomolecules (e.g., APO-E2 & E3,
glutathione or GSH, metallo-thionine, etc.).
It is also important to note that the "test tube
levels" of mercury are not representative of what
would happen in a dynamic system where a constant level of
mercury is being supplied by the amalgams. Since mercury
toxicity is a "retention toxicity" all mercury
pulled from the system, or retained by the tissue, is
replaced by more mercury being constantly released from
the amalgams and the Hg2+ level and toxicity in
solution remains constant. In the test tube as the mercury
is pulled out of solution the free Hg2+
concentration in solution drops making the soluble aspect
less toxic with time.
Are Amalgams Capable of Producing Toxic Solutions?
To propose deleterious effects of amalgams while in the
mouth the amalgams must be able to produce toxic effects
outside of the mouth. Wataha et al. reported that extracts
of the amalgam material (trade name, Dispersalloy)
"was severely cytotoxic when Zn release was greatest,
but less toxic between 48 and 72 hours as Zn release
decreased" (8). Zn is a trace material in dental
amalgams and a needed supplement for living neurons.
Therefore, it did not seem likely that the toxicity was
due to Zn emitting from the amalgams. When we compare the
toxicity of Hg2+ in brain homogenates as
described above (refs. 3 & 4), the addition of 0, 10
and 20 micromolar Zn2+ increased the inhibition
of GTP binding to tubulin from 4% to 50% and 76%,
respectively (7,13). This supports the concept that the Zn
correlation to increased toxicity was due to the
synergistically enhanced toxicity of the mercury released
from the amalgam. Further,other studies in our laboratory
have shown that soaking of amalgams in distilled water for
less than one hour created a solution that also caused
rapid inhibition of brain tubulin and creatine kinase
similar to that observed on adding Hg2+
solutions. Therefore, it appears that the toxicity of
solutions in which amalgams were soaked is not caused by
direct Zn2+ toxic effects. Rather, enhanced
toxicity is due to the Zn2+ or other amalgam
heavy metals stimulating the toxicity of mercury by
occupying biomolecule chelation sites. This would result
in a higher concentration of free Hg2+ capable
of inhibiting the activity of critical nucleotide binding
proteins such as tubulin and CK.
The observed synergistic toxicity of other heavy metals
with Hg2+ has been supported in animal models.
Combining an LD-1 solution of Pb2+ with an LD-1
solution of Hg2+ gave a solution with an LD of
100, instead of an LD-2, when injected into rats (19). The
bottom line is that mercury toxicity is enhanced by the
presence of other heavy metals. Therefore, when one
considers the toxicity of a certain body level of mercury
it is somewhat meaningless unless the body level of other
heavy metals is also considered.
With the complexity of our environment and the
confounding factors involving neurological diseases, and
without major government supported epidemiological studies
proving safety, it is impossible to state with assurance,
as many amalgams supporters do, that this exposure does
not place the individuals at greater health risk. The
"lack of proof of damage" from mercury exposure
seems unwarranted to be used as "proving the safety
of any material" that unnecessarily exposes
individuals daily to several micrograms of mercury.
Genetic Susceptibility Considerations.
Any hypothesis of the etiology of AD must consider
information on genetic susceptibility. The best known
genetic risk factor for AD is the correlation of APO-E
genotypes to the age of onset of AD (24a,b). Individuals
can inherit any combination of the alleles APO-E2, E3 or
E4. Individuals inheriting APO-E2 or combinations of
APO-E2 and E3 are much less likely to get early onset AD
than are individuals who have inherited APO-E4 genes.
Also, APO-E2 appears to be more protective than APO-E3
against early onset AD. Therefore, it is necessary that
the mechanism of mercury toxicity contain an explainable
relationship for the APO-E genetic susceptibility. This is
accomplished in a straight-forward manner by considering
the basic structural difference between these three
alleles. Simply put, the protective APO-E2 has two
sulfhydryls (cysteines) that can bind mercury or other
heavy metals that APO-E4 lacks. For example, in APO-E3,
one of APO-E2 cysteines is replaced by an arginine and in
APO-E4, both of the APO-E2 cysteines are replaced by
arginines (32). Therefore, lack of protection against
early onset AD was proposed to follow the loss of mercury
binding sulfhydryls from APO-E proteins (6).
The protection provided by APO-E2 is reasonable when
considering the nature and biochemical assignment of APO-E
proteins. APO-E proteins are involved in cholesterol
transport and all three alleles do this reasonably well.
However, APO-E is classified as a "housekeeping
protein". That is, in contrast to tubulin, GS and CK,
which are meant to stay inside of cells where they are
synthesized, APO-E is meant to leave the brain cells
carrying damaged cholesterol through the cerebrol spinal
fluid (CSF), across the blood-brain barrier into the blood
where it is removed by the liver. It fits into the
hypothesis that while APO-E2 or E3 are leaving the brain
cells and traversing the CSF they likely bind and remove
mercury, other heavy metals or other sulfhydryl reactive
toxins that may have made it into the central nervous
system thereby protecting the brain neurons (6). APO-E4
cannot as effectively bind mercury and therefore does not
provide the protective parameters that APO-E2 and E3 have.
It is interesting to note that the second highest level of
APO-E protein in the body is in the CSF that bathes and
protects the brain.
Oral Super-toxins Produced by Reaction With Dental
Mercury.
Many recent literature and popular press reports state
that the presence of periodontal disease raises the risk
factor or exacerbates the condition of several other
seemingly unrelated diseases such as stroke, low birth
weight babies, cardiovascular disease (See October 1996
issue of Periodontology). The anerobic bacteria of
periodontal disease produce hydrogen sulfide (H2S)
and methyl thiol (CH3SH) from cysteine and
methionine, respectively. This accounts for the "bad
breath" many individuals have.
However, in a mouth that produces H2S, CH3SH
(from periodontal disease) and Hgo (from
amalgam fillings) the very likely production of their
reaction products, HgS (mercury sulfide), CH3S-Hg-Cl
(methyl-thiol mercury chloride) and CH3S-Hg-S-CH3
(Dimethylthiol mercury) has to occur. This is simple,
straight-forward chemistry whose occurrence is supported
by easily observable "amalgam tattoos". These
tattoos are purple gum tissue surrounding certain teeth
where the gum and tooth meet and primarily caused by HgS
as determined by elemental analysis of such tissue.
HgS is one of the most stable forms of mercury
compounds and is the mineral form found in ore, called
cinnabar, from which mercury is mined from the earth. All
of these oral site produced compounds are classified as
extremely toxic and the latter compound, dimethylthiol-mercury
is very hydrophobic and its solubility would be similar to
dimethyl-mercury (CH3-Hg-CH3).
Dimethyl-mercury was the compound that was made famous in
the press where only a small amount spilled on the latex
gloves of a Dartmouth University chemistry professor
caused severe neurological problems and finally death 10
months later. In my opinion, the extreme lethality of CH3-Hg-CH3
compared to other forms of mercury is due to its ability
to collect in hydrophobic regions of the body, like the
central nervous system. CH3-Hg-CH3
is similar to CH3-S-Hg-S-CH3 in its
hydrophobic characteristics.
Logic implies that anyone with periodontal disease,
anaerobic bacterial infected teeth and mercury containing
fillings would be exposed daily to these very toxic
compounds. In our laboratory we synthesized the two
methylthiol-mercury compounds and tested them. They are
extremely cytotoxic at 1 micromolar or less levels and are
potent, irreversible inhibitors of a number of important
mammalian enzymes, including tubulin and CK.
A recent report stated that the tissues of individuals
who died of Idiopathic Dilated Cardiomyopathy (IDCM) had
mercury levels of 178,400 ng/g tissue or 22,000 times more
than their controls who died of other forms of heart
disease. IDCM is a disease where young athletes drop dead
during strenuous exercise. It seems impossible for a
tissue to bind this much mercury on protein without early
notice of injury through pain and lack of bioenergy.
However, if this mercury were to combine with H2S
produced by a local anerobic infection the mercury could
precipitate out in the tissue as HgS as it does in
"amalgam tattoos" causing a buildup without
killing the tissue immediately. However, one has to ask
where does this excess mercury come from. Many times this
occurs to young intercity athletes who are not on a high
seafood diet. My opinion is that dental amalgam is the
source of this mercury. Also, if HgS is being made in the
heart tissue the very cytotoxic CH3-S-HgX and
CH3-S-Hg-S-CH3 are also being made.
To determine if toxic teeth could have an effect on the
enzymes/proteins of human brain we have done the following
study. Several very toxic teeth were incubated for 1 hour
in distilled water. Aliquots of these solutions were then
added to control human brain homogenates and the resulting
samples tested for tubulin viability and partitioning. The
results showed that about 40% inhibited the viability of
tubulin and caused partitioning. Therefore, depending on
the type of anerobic microbial infection existing in
avital teeth it is possible to have a toxicant production
that would exacerbate the condition classified as AD. It
is also probable that many of these teeth were extracted
from mouths containing amalgam and the toxins in these
teeth may also consist partially of extremely
organic-mercury compounds as described above.
Based on the potential clearance represented by
elevated blood levels of mercury in early onset AD
patients, the synergistic effects of other heavy metals,
the fluctuating GSH levels during illness and aging, and
dietary factors (e.g. selenium levels) there is no reason
to believe that the adverse effects of mercury from
amalgams would be dose dependent in any straight-forward
manner in post-mortem AD brain. To expect this would fly
in the face of published data and scientific logic.
Further, to eliminate mercury as a factor in AD based on
statistically insignificant increases above normal in
post-mortem brain samples is not warranted. Also,
involvement of genetic factors likely plays a key role.
Studies Involving Neuronal Cultures and Diagnostic
Markers for AD.
A recent publication supports our contention that
mercury from dental amalgams poses a major threat to the
exacerbation of AD. Olivieri et al. demonstrated that
exposure of neuroblastoma cells to sub-lethal doses (36 X
10-9 molar) of Hg2+ caused a rapid
drop in GSH, an increased secretion of b–amyloid
protein and an increased phosphorylation of the
microtubulin protein Tau (17). The latter two of these
biochemical changes are uniquely observed in AD brain
tissues and are widely considered to be diagnostic,
pathological markers of the disease. b-amyloid
protein makes up the ‘amyloid plaques’ that was one of
the first diagnostic markers reported for AD brain
pathology. A very strong component of AD researchers
believe that amyloid protein is the cause of AD.
Therefore, mercury exposure at nanomolar levels causes
neuroblastoma cells to produce a protein that is believed
to be involved directly in AD. This lead the authors of
this paper to conclude that mercury would have to be
consider as causal for AD (17).
Further, the recent report of the response of neurons
in culture rapidly forming neurofibillary tangles on
exposure to extremely low levels of mercury, by a process
involving loss of microtublin structure, completes the
picture that mercury is capable of causing the formation
of three widely accepted major pathological diagnostic
hallmarks of AD in neuronal cultures (18). An impressive
video accompanying this publication and available at http://movies.commons.ucalgary.ca/mercury
shows the addition of 2 microliters of 10-7M
mercury to a 2 milliliter solution bathing neurons caused
a rapid stripping of the tubulin from the neurofibrils
leaving them bare. This would be predictable from our
earlier data showing mercury interfering with normal
tubulin-GTP interactions and the abnormal partitioning of
tubulin into the particulate fraction of brain
tissue(3,4,6). The bare neurofibrils then aggregate
forming neurofibrillary tangles (NFTs) similar to those
observed in AD brain. The final mercury concentration of
10-10M in these experiments is roughly 100 to
1000 times lower than the 10-7M levels normally
found in human brain of individuals with amalgam fillings.
The majority of the mercury in brain is likely bound by
protective compounds like GSH or selenium and not free to
cause neuronal damage. However, it is not unreasonable to
consider that some of this mercury is present as free Hg2+
some fraction of the time, especially when illness or
other toxicities lower the GSH levels.
However, these two recent publications supports the
initial contention that mercury first rapidly inhibits
thiol-sensitive enzymes like tubulin, creatine kinase and
glutamine synthetase and dramatically affects metabolism
and membrane structure. The stripping of tubulin leads to
the formation of NFTs and the exposing Tau for hyper-phosphorylation.
This is followed by elevated production of b
–amyloid protein that can aggregate into senile plaques.
all diagnostic markers for AD. It is consistent with the
mercury toxicity hypothesis for AD that neurofibillary
tangles, hyper-phosphorylated Tau, amyloid plaques and
increased oxidative stress observations are the result of
neuronal toxicity and death in AD, they are not the cause.
The cause is exposure to environmental toxicants like
mercury that attack enzymes with the most reactive thiol
groups.
CONCLUSION:
The data on the effects of mercury on the nucleotide
binding properties and the abnormal partitioning of two
very important brain nucleotide binding proteins proven to
be aberrant in AD brain first suggested that mercury must
be considered as an exacerbating factor to the condition
classified as AD. This has been strongly supported by the
recent finds that nanomolar levels of mercury causes
neuroblastoma cells to secrete b-amyloid
protein and increase phosphorylation of the microtubulin
associated protein Tau, both major biochemical
observations related to AD. Also, neurons in culture
exposed to Hg2+ at the 10-7 to 10-10
M levels have conclusively been visually shown to
rapidly produce abnormal tubulin aggregation, resulting in
particulate partitioning as observed in AD brain. Also,
this stripping of tubulin from the neurofibrils results in
the formation of NFTs that are indistinguishable from
those observed in AD brain. and used as a diagnostic
marker of the disease(18). These facts alone warrant
serious consideration of mercury as a certain exacerbating
factor for AD, if not causal.
Consideration of mercury as a causal or exacerbating
factor for AD is especially relevant when mercury is
present in combination with other heavy metals such as
zinc (Zn) cadmium (Cd) and lead (Pb). Synergistic toxicity
is not an exception but is observed as a general rule
(19). This obviates the argument that mercury must be
significantly elevated in AD brains to be considered
causal or contributing to the disease state. Further, the
reaction of oral mercury from amalgams with toxic thiols
produced by periodontal disease bacteria very likely
enhances the toxicity of the mercury being released.
Humans are likely the only mammals with amalgam fillings
and periodontal disease. Bluntly, the determination of
safe body levels of mercury by using animal data where the
animals have not been exposed to other heavy metals is not
scientifically justifiable. Mercury is much more toxic to
individuals with other heavy metal exposures. It is my
opinion that one of the major unanswered questions
concerning the toxic effects of mercury is "does the
combination of mercury with different heavy metals lead to
different clinical observations of toxicity?"
Finally, mercury biochemically mimics numerous
observations seen in AD brain tissues including inducing
the formation of widely accepted diagnostic hallmarks of
the disease. Further, the synergistically toxicity of
mercury with other heavy metals, microbial produced oral
toxins and certain metal chelators is obvious. It is also
a scientific fact that amalgams contribute greatly to
overall mercury body burden and are capable of producing
cytotoxic solutions with properties like mercury
solutions. Therefore, it seems very reasonable to consider
a hypothesis that mercury would be the major contributor
to early onset AD.
Bibliography
1. Khatoon, S., Campbell, S.R., Haley, B.E. and Slevin,
J.T. Aberrant GTP b-Tubulin
Interaction in Alzheimer’s Disease. Annals of
Neurology 26, 210-215 (1989).
2. David, S., Shoemaker, M., and Haley, B. Abnormal
Properties of Creatine kinase in Alzheimer’s Disease
Brain: Correlation of Reduced Enzyme Activity and Active
Site Photolabeling with Aberrant Cytosol-Membrane
Partitioning. Molecular Brain Research 54, 276-287 (1998).
3. Duhr, E.F., Pendergrass, J. C., Slevin, J.T., and
Haley, B. HgEDTA Complex Inhibits GTP Interactions With
The E-Site of Brain b-Tubulin
Toxicology and Applied Pharmacology 122, 273-288
(1993).
4. Pendergrass, J.C. and Haley, B.E. Mercury-EDTA
Complex Specifically Blocks Brain b-Tubulin-GTP
Interactions: Similarity to Observations in
Alzheimer"s Disease. pp98-105 in Status Quo and
Perspective of Amalgam and Other Dental Materials
(International Symposium Proceedings ed. by L. T. Friberg
and G. N. Schrauzer) Georg Thieme Verlag, Stuttgart-New
York (1995).
5. Pendergrass, J. C., Haley, B.E., Vimy, M. J.,
Winfield, S.A. and Lorscheider, F.L. Mercury Vapor
Inhalation Inhibits Binding of GTP to Tubulin in Rat
Brain: Similarity to a Molecular Lesion in Alzheimer’s
Disease Brain. Neurotoxicology 18(2), 315-324
(1997).
6. Pendergrass, J.C. and Haley, B.E. Inhibition of
Brain Tubulin-Guanosine 5’-Triphosphate Interactions by
Mercury: Similarity to Observations in Alzheimer’s
Diseased Brain. In Metal Ions in Biological Systems V34,
pp 461-478. Mercury and Its Effects on Environment and
Biology, Chapter 16. Edited by H. Sigel and A. Sigel.
Marcel Dekker, Inc. 270 Madison Ave., N.Y., N.Y. 10016
(1996).
7. Pendergrass, J.C., David, S. and Haley, B. Aberrant
GTP-Tubulin Interactions and Aberrant –Tubulin
Partitioning in Alzheimer’s Disease Brain are Induced In
Vitro by Micromolar Mercury, Zinc and other Sulfhydryl
Reactive Heavy Metals. (in preparation 1998).
8. Wataha, J. C., Nakajima, H., Hanks, C. T., and
Okabe, T. Correlation of Cytotoxicity with Element Release
from Mercury and Gallium-based Dental Alloys in vitro.
Dental Materials 10(5) 298-303, Sept. (1994)
9. Chew, C. L., Soh, G., Lee, A. S. and Yeoh, T. S.
Long-term Dissolution of Mercury from a
Non-Mercury-Releasing Amalgam. Clinical Preventive
Dentistry 13(3): 5-7, May-June (1991).
10. Thompson, C. M., Markesbery, W.R., Ehmann, W.D.,
Mao, Y-X, and Vance, D.E. Regional Brain Trace-Element
Studies in Alzheimer’s Disease. Neurotoxicology 9, 1-8
(1988).
11. Deibel, M. A., Ehmann, W.D., and Markesbery, W. R.
Copper, Iron and Zinc Imbalances in Severely Degenerated
Brain Regions in Alzheimer’s Disease: Possible Relation
to Oxidative Stress. J. Neurol. Sci. 143, 137-142 (1996).
12. Gunnersen, D.J. and Haley, B. Detection of
Glutamine Synthetase in the Cerebrospinal Fluid of
Alzheimer’s Diseased Patients: A Potential Diagnostic
Biochemical Maker. Proc. Natl. Acad. Sci. USA, 88,
11949-11953 (1992).
13. Pendergrass, J. C., Cornett, C.R., David, S. and
Haley, B. Mercury and Zinc Levels in Frontal Pole and
Hippocampus of Alzheimer’s Disease Brain: Relationship
to Abberant GTP-b-Tubulin
Interactions. Submitted to Neurotoxicology (1998).
14. Jayaram, B. and Haley, B. Identification of
Peptides Within the Base Binding Domains of the GTP and
ATP Specific Binding Sites of Tubulin. J. Biol. Chem.
269 (5) 3233-3242 (1994).
15. Olcott, M. and Haley, B. Identification of Two
Peptides From the ATP-Binding Domain of Creatine Kinase. Biochemistry,
33, 11935-11941 (1994).
16. Tumani, H., Shen, G-Q., Peter, J. and Bruck, W.
Glutamine Synthetase in Cerebrospinal Fluid, Serum and
Brain: A Diagnostic Marker for Alzheimer Disease? Arch.
Neurol. 56, 12411246, 1999.
17. Olivieri, G., Brack, Ch., Muller-Spahn, F.,
Stahelin, H.B., Herrmann, M., Renard, P; Brockhaus, M. and
Hock, C. Mercury Induces Cell Cytotoxicity and Oxidative
Stress and Increases b-amyloid
Secretion and Tau Phosphorylation in SHSY5Y Neuroblastoma
Cells. J. Neurochemistry 74, 231-231, 2000.
18. Leong, CCW, Syed, N.I., and Lorscheider, F.L.
Retrograde Degeneration of Neurite Membrane Structural
Integrity and Formation of Neruofibillary Tangles at Nerve
Growth Cones Following In Vitro Exposure to Mercury.
NeuroReports 12 (4):733-737, 2001.
19. Schubert, J., Riley, E.J. and Tyler, S.A., Combined
Effects in Toxicology—A Rapid Systemic Testing
Procedure: Cadmium, Mercury and Lead. J. of Toxicology and
Environmental Health v4;763-776, 1978.
20. Kingman, A., Albertini, T. and Brown, L.J. Mercury
Concentrations in Urine and Whole Blood Associated with
Amalgam Exposure in a US Military Population. J. of Dental
Research v77(3): 461-471, 1998.
21. B. E. Haley, "Development and Utilization of
8-Azidopurine Nucleotide Photoaffinity Probes," Federation
Proceedings, 42, 2831-2836 (1983).
22. K. Hensley, P. Cole, R. Subramaniam, M. Aksenov, M.
Aksenova, P. M. Bummer, B. E. Haley, J. M. Carney and D.
A. Butterfield, , "Oxidatively-Induced Structural
Alteration of Glutamine Synthetase Assessed by Analysis of
Spin Labeled Incorporation Kinetics: Relevance to
Alzheimer’s Disease," J. Neurochem., 68,
2451-2457 (1997).
23. Begerow, J., Zander, D., Freier, I. And Dunemann,
L. Long-term Mercury Excretion in Urine after Removal of
Amalgam Fillings. Int. Arch. Occup. Environ. Health v66
(3), 209-212, 1994.
24. (a)Roses, A.D. Scientific American. Science and
Medicine. 16-25, 1995. (b)Roses, A.D. Apolipoprotein-E and
Alzheimer’s Disease. The Tip of the Susceptibility
Iceberg. Annals of the N.Y. Academy of Science 855,
738-743, 1998.
25. Saxe, S.R., Wekstein, M.W., Kryscio, R.J., Henry,
R.G., Conrett, C.R., Snowdon, D.A., Grant, F.T., Schmitt,
F.A., Donegan, S.J., Wekstein, D.R., Ehmann, W.D. and
Markesbery, W.R. Alzheimers’ Disease, Dental Amalgam and
Mercury. JADA 130, 191-199, 1999.
26. Lorscheider, F.L., Vimy, M.J. and Summers, A.O.
Mercury Exposure from Silver Tooth Fillings: Emerging
Evidence Questions a Traditional Dental Paradigm. FASEB J.
9, 504-508, 1995.
27. Hock, C. Drasch, G. Golombowski, S., Muller-Spahn,
F., Willershausen-Zonnchen, B., Schwarz, P., Hock, U.
Growdon, J.H. and Nitsch, R.M. Increased Blood Mercury
Levels in Patients with Alzheimer’s disease. J. of
Neural Transmission v105L 1)
59-68, 1998.
28. Devanand, D.P., Michaels-Marston, K.S., Liu, X.,
Pelton, G.H., Padilla, M., Marder, K., Bell, K., kStern,
Y., and Mayeux, R. Olfactory Deficits in Patients with
Mild Cognitive Impairment Predict Alzheimer’s Disease at
Follow-up. Am. J. Psychiatry 157(9): 1399-1405, 2000.
29. Kovacs, T., Cairns, N.J., Lantos, P.L. Olfactory
Centres in Alzheimer’s disease: Olfactory Bulb is
Involved in Early Braak’s Stages. Neuroreport 12(2):
285-288, 2001.
30. Gray, A.J., Staples, V., Murren, K., Dahariwal, A.
and Bentham, P. Olfactory Identification is Impaired in
Clinic-Based Patients with Vascular Dementia and Senile
Dementia of Alzheimer’s type. Int. J. Geriatr.
Psychiatry 16(5):513-517, 2001.
31. World Health Organization (WHO) report on
Environmental Health Criteria 118, Inorganic Mercury, WHO,
Genevia, 1991.
32. Brouwer, D.A., Clinical Chemistry of Common
Apoprotein-E Isoforms. J. Chromatography, Biomed.
Applications, v678(1) 23-41, 1996.